In clinical trials, Antara reduced cardiovascular-related events by nearly 30% in patients with low HDL-C & High TGs

About
ANTARA®

For the treatment of primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia as adjunctive therapy to diet

In patients with low HDL-C and high TG, the addition of fenofibrate lowered cardiovascular-related events by approximately 30%1,2

  • Although the addition of fenofibrate did not reduce CHD events and CHD-related mortality in the entire study population, patients with low HDL-C (<34 mg/dL) and high TG levels (>204 mg/dL) at baseline did experience a clinical benefit1
  • CHD-related events or death were reduced by approximately 30% in this subset of patients1
  • The value in this group was 0.057, which falls short of being statistically significant1,2

Important limitations of use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.

Enlarge ACCORD sub-study on patients experiencing MI, stroke, or cardiovascular-related death

ACCORD Sub-study1

Patients Experiencing MI, Stroke, or Cardiovascular-Related Death2

Patients with low HDL-C and high TG levels experienced clinical benefit from fenofibrate adjunctive therapy ACCORD study on cardiovascular event reduction in patients treated with adjunctive fenofibrate therapy vs. statin treatment only
References
  1. ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.
  2. Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses. Diabetes Care. 2011;34(Suppl. 2): S106-108.